Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kamada-AAT for Inhalation in congenital alpha-1 antitrypsin deficiency with airflow limitation
NL-OMON59990Phase 3Completed
- Sponsor
- Kamada Ltd.
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpha1-proteinase inhibitor (human) in alpha-1 antitrypsin deficiency (AATD) and chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Kamada Ltd. Primary endpoint: Post-bronchodilator FEV1 change from baseline at 104 weeks. Started Oct 2019; status: completed.
02
Drugs
alpha1-proteinase inhibitor (human)
03
Conditions
alpha-1 antitrypsin deficiency (AATD)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON59990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59990.